AstraZeneca reportedly in merger talks with BMS
UK pharma major AstraZeneca (LSE: AZN) has been in talks in recent months to combine with US rival Bristol Myers Squibb (NSE: BMY), about a deal that would create one of the world’s biggest pharmaceutical groups, valued at nearly $400 billion, according to a report by the Financial Times.
AstraZeneca, the UK’s second most valuable listed company, has a market value of about £196 billion ($264 billion), while BMS is worth roughly $133 billion. A combination of the two would be among the biggest pharmaceutical deals of all time, and propel the combined entity to become the world’s fourth-largest drugmaker by market capitalisation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze